Assembly Biosciences, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Assembly Biosciences, Inc. (ASMB) had Debt Securities, Available-for-sale, Unrealized Loss Position of $0 as of 2025-12-31, per its 10-Q filed 2026-08-13.
Financial Statements › Notes
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-13
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
- 2024-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $0.00.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position |
|---|---|
| 2025-12-31 | $0.00 10-Q · filed 2026-08-13 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |